SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-20-019642
Filing Date
2020-07-31
Accepted
2020-07-31 16:20:47
Documents
60
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0620_protaratherape.htm 10-Q 905137
2 RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY f10q0620ex10-1_protara.htm EX-10.1 14125
3 SEPARATION AGREEMENT AND RELEASE, DATED AS OF JULY 23, 2020, BY AND BETWEEN THE f10q0620ex10-2_protara.htm EX-10.2 53442
4 CERTIFICATION f10q0620ex31-1_protara.htm EX-31.1 16719
5 CERTIFICATION f10q0620ex31-2_protara.htm EX-31.2 16943
6 CERTIFICATION f10q0620ex32-1_protara.htm EX-32.1 10646
  Complete submission text file 0001213900-20-019642.txt   3666562

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE FILE tara-20200630.xml EX-101.INS 504187
8 XBRL SCHEMA FILE tara-20200630.xsd EX-101.SCH 47646
9 XBRL CALCULATION FILE tara-20200630_cal.xml EX-101.CAL 42459
10 XBRL DEFINITION FILE tara-20200630_def.xml EX-101.DEF 139588
11 XBRL LABEL FILE tara-20200630_lab.xml EX-101.LAB 291635
12 XBRL PRESENTATION FILE tara-20200630_pre.xml EX-101.PRE 228794
Mailing Address 1 LITTLE WEST 12TH STREET NEW YORK NY 10014
Business Address 1 LITTLE WEST 12TH STREET NEW YORK NY 10014 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36694 | Film No.: 201066217
SIC: 2836 Biological Products, (No Diagnostic Substances)